Gain Therapeutics, Inc.

NASDAQ:GANX

Biotechnology

Healthcare
$1.18 +3.09%

+$0.06 today

Market cap
$50.33M
Beta
0.16
P/E (TTM)
-3.6
EPS (TTM)
-$0.50
52W Low $1.41High $4.34

Volume 4.26M

Average 0.64M

GANX Other Non-Cash Items

Other non-cash adjustments that reconcile net income to operating cash flow.

Gain Therapeutics, Inc.NASDAQ: GANX

Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026

Other non-cash items growth accelerates

Q1 FY2026 other non-cash items of $230.46K rose 110.3% year over year, ahead of the +104.3% change in trailing-twelve-month other non-cash items. Sequentially, it rose 1958.8% from the prior quarter.

Context

  • Other non-cash items increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +110.3% holds above the trailing-twelve-month pace of +104.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$230.46K+1958.8% QoQ
Last fiscal yearDec 2025
$804.94K+460.8% YoY
LTMMar 2026
$925.81K+104.3% YoY
Other Non-Cash Items past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+110.3%——
1 year+460.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Non-Cash Items history

USD · from the cash flow

Latest · FY2025
804.94K USD
Year-over-year change
+460.8%
4-year CAGR
-5.3%

Other Non-Cash Items vs competitors

How GANX compares with its peers on the latest reported figures

  • GANX's LTM Mar 2026 other non-cash items of $925.81K is the 7th largest of the 9 companies compared; the peer median is $976.5K.
  • Its year-over-year change of +104.3% is the 3rd highest of 8, against a peer median of -28.0%.
GANX Competitors Peer median
Other Non-Cash Items for GANX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OSTXOS Therapies IncorporatedLTM Mar 2026$24.1B +2791176.7%+1768.5%—
ADAGAdagene Inc.LTM Jun 2024$10.13M —-13.8%1241.7%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$7.27M -28.0%—317.0%
FBIOFortress Biotech, Inc.LTM Mar 2026$5.8M -19.8%—8.8%
ACETAdicet Bio, Inc.LTM Mar 2026$1.92M +141.4%+11.0%—
XBITXBiotech Inc.LTM Mar 2026$1.58M -143.2%——
GANXGain Therapeutics, Inc.LTM Mar 2026$925.81K +104.3%——
TCRXTScan Therapeutics, Inc.LTM Mar 2026$660K -77.6%—7.2%
NTRBNutriband Inc.LTM Apr 2026$36K -99.3%+63.2%2.0%
Peer median (excluding GANX) $976.5K-28.0%+37.1%8.8%

Competitors are the stored peer set for GANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(13.89M)(17.59M)(22.27M)(20.41M)(20.16M)
Depreciation & Amortization15.48K64.17K83.58K84.07K94.05K
Deferred Income Tax00000
Stock-Based Compensation839.37K1.53M3.26M2.39M1.8M
Change in Working Capital(329.78K)1.51M442.23K(1.08M)(1.01M)
Accounts Receivables(63.35K)3.63K000
Inventory00000
Accounts Payables(521.39K)1.07M(643.16K)274.89K(468.61K)
Other Working Capital254.96K444.52K1.09M(1.36M)(537.91K)
Other Non-Cash Items999.87K(206.86K)(383.19K)143.52K804.94K
Operating Cash Flow(12.37M)(14.69M)(18.87M)(18.87M)(18.47M)
Capital Expenditures(94.21K)(118.95K)(15.36K)(22.49K)0
Acquisitions (Net)00000
Purchases of Investments0(17.74M)(1.96M)00
Sales of Investments03.08M12.19M5M0
Other Investing Activities00000
Investing Cash Flow(94.21K)(14.77M)10.22M4.98M0
Debt Repayment(21.95K)(78.77K)(89.07K)(90.88K)(96.5K)
Common Stock Issued42.63M012.73M13.21M28.54M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(841.27K)00(109.36K)0
Financing Cash Flow41.77M(78.77K)12.64M13.01M28.45M
Effect of Forex Changes100.78K(23.8K)488.4K(527.17K)469.43K
Net Change in Cash29.41M(29.57M)4.49M(1.41M)10.46M
Free Cash Flow(12.46M)(14.81M)(18.88M)(18.9M)(18.47M)

Gain Therapeutics, Inc.

NASDAQ:GANX

Intrinsic Alpha fair value

Locked

Current Price

$1.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.